Barely Significant
← all excerpts

MALNC: a new mutant NPM1/IDH2<sup>R140</sup> and PML-RARA-associated lncRNA with impact on AML cell proliferation, maturation and drug response.

Cancer Gene Ther · 2025 · PMC12620280 · PMID 40849353

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
Interestingly, arsenic trioxide (ATO), a standard therapy for APL when combined with ATRA, showed a trend toward increased sensitivity in NB4- MALNC KO cells in the DSRT screen (sDSS = 1.633).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.